Risk of immune checkpoint inhibitor–related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease: A propensity score–matched analysis.
Rattachement africain : us, jo. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
e20596 Background: Immune checkpoint inhibitors (ICIs) are standard therapy for non-small cell lung cancer (NSCLC) but can cause immune-related pneumonitis. Patients with chronic obstructive pulmonary disease (COPD) may be at increased risk, though real-world data are limited. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network to identify adults with NSCLC who initiated ICI therapy between 2015-2022. Patients were stratified by COPD status. Exclusion criteria include secondary malignancies, autoimmune disease, or pre-existing pneumonitis. Propensity score matching (1:1) was performed based on age, sex, race, ethnicity, comorbidities (hypertension, ischemic heart disease, cerebrovascular disease, chronic kidney disease), and prior radiation therapy. The primary outcome was pneumonitis within 2 years of ICI initiation. Secondary outcomes included all-cause mortality, all-cause hospitalization, and ICU admission. Results: Before matching, 3,234 patients with COPD and 5,967 patients without COPD were identified. After propensity score matching, 2,914 patients were included in each cohort. Baseline characteristics and comorbid conditions were well-balanced between the two cohorts: mean age 73 years, 55% male, hypertension (51%), ischemic heart disease (21%), cerebrovascular disease (12%), and chronic kidney disease (11%). Pneumonitis occurred in 8.6% (n = 251) of patients with COPD versus 4.2% (n = 122) without COPD. COPD was associated with significantly increased risk of pneumonitis (HR 1.88, 95% CI 1.51-2.33; log-rank p<0.001). All-cause mortality and hospitalization rates were similar between cohorts; however, ICU admission was more common in patients with COPD (9.4% vs 6.0%; hazard ratio 1.44, 95% CI 1.19–1.75; p < 0.001). Conclusions: Among patients with NSCLC treated with ICIs, pre-existing COPD was associated with nearly 2-fold increased risk of pneumonitis. These findings highlight the need for enhanced monitoring and risk-stratified management of patients with COPD receiving immunotherapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Risk of immune checkpoint inhibitor–related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease: A propensity score–matched analysis.
- Date Crossref
- 01/06/2026
- Éditeur
- American Society of Clinical Oncology (ASCO)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
New York Medical College pays non établi dans la noticeUniversité ou école supérieure
-
Saint Michael's Medical Center pays non établi dans la noticeÉtablissement de santé
-
Jefferson Hospital pays non établi dans la noticeÉtablissement de santé
-
Saint Francis Hospital pays non établi dans la noticeÉtablissement de santé
-
Mutah University pays non établi dans la noticeUniversité ou école supérieure
-
Community Health Systems - Crestwood Medical Center pays non établi dans la noticeÉtablissement de santé
-
Jefferson Einstein Philadelphia Hospital pays non établi dans la noticeÉtablissement de santé
-
Mu'tah University pays non établi dans la noticeUniversité ou école supérieure
-
St. Michael's Medical Ctr pays non établi dans la noticeInstitution
-
Reg Cancer Center at St Michael's Medical Center pays non établi dans la noticeÉtablissement de santé
New York Medical College, Saint Michael's Medical Center et Jefferson Hospital, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.